NCT03541148

Evaluation of Oncoxin-Viusid® in Cutaneous Melanoma

Evaluation of the Nutritional Supplement Oncoxin-Viusid® in the Treatment of 20 Patients With Cutaneous Melanoma in Stage IIB-IIIA

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 20 (actual)
• Sponsor: Catalysis SL · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Accepted

Summary

Malignant melanoma, responsible for 75% of deaths from skin cancer. Current therapeutic options have poor response, many adverse events and high costs. For this reason, a study with nutritional supplement Oncoxin-Viusid was carried out. According to previous studies, it has an antitumor, immunomodulatory effect and to potentiate the antiproliferative effect of standard chemotherapeutic agents in different locations and stages of cancer.

Detailed description

Performed at Manuel Fajardo Surgical Clinical University Hospital in Havana, Cuba from September 2014 to April 2018, following a proof of concept open label study, with no control group in 20 patients diagnosed histologically in Fajardo Hospital or Oncology Institute, as Melanoma, primary cutaneous stage IIB-IIIA. All received conventional surgical treatment and oral Oncoxin-Viusid (25 ml 2 times a day for one year), where it was also indicated adjuvant treatment or chemotherapy. All were evaluated monthly the first year and semesterly the second year. Complying with the provisions of the Helsinki Act.

Conditions

• Cutaneous Melanoma, Stage II
• Malignant Cutaneous Melanoma
• Cutaneous Melanoma, Stage III

Interventions

Type	Name	Description
DIETARY_SUPPLEMENT	Oncoxin-Viusid	Oncoxin-Viusid supplement before/during/after standard surgical and adjuvant treatment or chemotherapy.

Timeline

• Start date: 2014-09-16
• Primary completion: 2016-04-13
• Completion: 2018-04-13
• First posted: 2018-05-30
• Last updated: 2018-05-30

Locations

1 site across 1 country: Cuba